阿尔茨海默病及其治疗药物研究进展  

Recent advances in Alzheimer's disease and its drug discovery

作　　者：朱杰 张钊[1] 董一筱 陈乃宏[1] ZHU Jie;ZHANG Zhao;DONG Yi-xiao;CHEN Nai-hong(Institute of Materia Medica,Peking Union Medical College,Chinese Academy of Medical Sciences,Beijing 100050,China;State Key Lab of Biochemical Engineering,Institute of Process Engineering,Chinese Academy of Sciences,Beijing 100190,China;Tianjin University of Traditional Chinese Medicine,Tianjin 300193,China)

机构地区：[1]中国医学科学院北京协和医学院药物研究所神经科学中心,北京100050 [2]中国科学院过程工程研究所生化工程国家重点实验室,北京100190 [3]天津中医药大学药学院,天津300193

出　　处：《中国药理学通报》2018年第12期1629-1634,共6页Chinese Pharmacological Bulletin

基　　金：中国医学科学院医学健康与科技创新工程经费资助(No 2016-I2M-1-004);国家自然科学基金资助项目(No 81603316;81603315);湖南省中药饮片标准化及功能工程技术研究中心开放基金资助项目(No BG201701)

摘　　要：阿尔茨海默病(Alzheimer’s disease, AD)是导致全球老年人死亡的神经类重大疾病之一,AD患者生活往往不能自理,给患者及其家属带来严重负担。AD的发病机制目前尚未研究清楚,β淀粉样蛋白级联假说是当前公认的AD发病机制。在该假说基础上,一些新的AD发病机制,如Tau异常磷酸化、昼夜节律、易感基因、炎症学说等都会对AD进程产生影响。免疫疗法、外泌体的研究、光刺激等新的治疗AD的方法也逐渐出现。该文主要以AD研究进展为依据,阐述AD可能的发病机制及其药物研发的新方向。Alzheimer s disease （AD） is the third major disease leading to the death of old people in the world. AD patients often fail to take care of themselves, and bring serious burden to the patients and their families. To date, the pathogenesis of AD has not been clearly understood, and according to the beta amyloid cascade hypothesis, the drugs targeting beta amyloid have failed in clinical trial. On the basis of beta amyloid pathogenesis theory, some new AD mechanisms such as abnormally hyperphosphorylated of Tau, circadian rhythms, risk gene, inflammation theory were found. The new treatment for AD, such as immunotherapy, exosomes, and light stimulation, is emerging. Based on the latest research, the possible pathogenesis of AD and the new direction of drug development are described in this paper.

关 键 词：阿尔茨海默病 研究进展 Β淀粉样蛋白 易感基因 药物研发 外泌体 

分 类 号：R-05[医药卫生] R745.702.2